Generation and molecular characterization of a monoclonal antibody reactive with conserved epitope in sphingomyelinases D from Loxosceles spider venoms  by Dias-Lopes, C. et al.
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a  b  s  t  r  a  c  t
We  report  the  production  of  a neutralizing  monoclonal  antibody  able  to recognize  the  venoms  of three
major  medically  important  species  of  Loxosceles  spiders  in  Brazil.  The  mAb  was  produced  by immuniza-
tion  of  mice  with  a toxic  recombinant  L.  intermedia  sphingomyelinase  D  {SMases  D  isoform  (rLiD1)}  [1]
and  screened  by enzyme-linked  immunosorbent  assay  (ELISA)  using  L.  intermedia,  L.  laeta  and  L.  gaucho
venoms  as  antigens.  One  clone  (LiD1mAb16)  out of  seventeen  anti-rLiD1  hybridomas  was  cross-reactive
with  the  three  whole  Loxosceles  venoms.  2D  Western  blot  analysis  indicated  that  LiD1mAb16  was capable
of  interacting  with  34  proteins  of 29–36  kDa  in  L. intermedia,  33  in  L. gaucho  and  27  in L.  laeta  venoms.phingomyelinases D
onoclonal  antibody
pitopes
The  results  of immunoassays  with  cellulose-bound  peptides  revealed  that  the LiD1mAb16  recognizes  a
highly  conserved  linear  epitope  localized  in the  catalytic  region  of  SMases  D  toxins.  The  selected  mAb
displayed  in  vivo  protective  activity  in  rabbits  after  challenge  with  rLiD1.  These  results  show  the  potential
usefulness  of monoclonal  antibodies  for  future  therapeutic  approaches  and  also  opens  up the  perspective
of  utilization  of  these  antibodies  for  immunodiagnostic  assays  in loxoscelism.
© 2014  Elsevier  Ltd.  All  rights  reserved.. Introduction
The spiders Loxosceles intermedia, L. laeta and L. gaucho are a
roup of arachnids known as “brown spider” with medical impor-
ance in the South and South-east of Brazil [2,3]. The number of
uman accidents caused by spiders of this genus in Brazil has
eached almost 7000 annually [4]. Loxoscelism, the term used
or envenomations with Loxosceles spiders, can be observed as
wo well-deﬁned clinical variants: cutaneous loxoscelism and
ystemic loxoscelism. Pain, edema, and livedoid plaque, which
evelop later into a necrotic scar, are the predominant local man-
festations in cutaneous loxoscelism, occurring in around 83% of
he cases. In systemic loxoscelism, hematuria and hemoglobin-
ria are always observed, whereas intravascular hemolysis and
∗ Corresponding author at: Departamento de Bioquímica e Imunologia, Instituto
e Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Car-
os, CEP: 31.270.901, 6627 Belo Horizonte, Brazil. Tel.: +55 31 3409 2625;
ax: +55 31 3409 2613.
E-mail  address: olortegi@icb.ufmg.br (C. Chávez-Olortegui).
ttp://dx.doi.org/10.1016/j.vaccine.2014.02.012
264-410X/© 2014 Elsevier Ltd. All rights reserved.coagulation, sometimes accompanied by thrombocytopenia and
renal  failure, occur in approximately 16% of the victims [5–7]. Anti-
venom therapy is used to neutralize the circulating venom and
reduces the risk of fatal complications following human accidents
[8]. The anti-loxoscelic antivenom is the polyspeciﬁc serum that
containing antibodies against whole venoms of the three Loxosce-
les species (L. gaucho, L. laeta and L. intermedia) and is produced
at Centro de Producão e Pesquisa de Imunobiológicos (CPPI) of the
State of Paraná, Brazil [9].
Proteins of the phospholipase D family also named sph-
ingomyelinase D (SMase D), or dermonecrotic proteins, are
responsible for the necrotic skin lesions and also for systemic
toxic effects following envenomation by Loxosceles spiders [10–13].
Loxosceles venoms express SMases D isoforms and these proteins
constitute a family of homologs with 190 non-redundant sequences
described in 21 species of the Sicariidae family [14]. SMase D
proteins are also the most antigenic/immunogenic components
of the venom [15]. Monoclonal and polyclonal antibodies against
Loxosceles whole venoms generally recognize dermonecrotic pro-
teins [16,17]. Neutralizing monoclonal antibodies (mAbs) open
new perspectives to employment of these antibodies in loxoscelism
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reatment or diagnosis. However, all neutralizing mAbs produced
ntil now recognize effectively only the venom species-speciﬁc
15,17].
In the present work, we produced a mAb  able to recognize the
enoms of the three major medically important species of Loxosce-
es spiders in Brazil. These mAb  was obtained by immunization
f mice with recombinant L. intermedia Smase D isoform (rLiD1)
1] and screened by enzyme-linked immunosorbent assay (ELISA)
sing L. intermedia, L. laeta and L. gaucho whole venoms as anti-
ens coated onto micro titer plates, so as to drive selection toward
ross-reactive antibodies. The mAb  namely LiD1mAb16 was able
o recognize a large range of proteins antigens (at least 25) in
ach of the three Loxosceles venom. Epitope-mapping experiments
evealed that it recognizes a highly conserved linear epitope located
n the catalytic region of SMases D toxins. LiD1mAb16 displayed
 protective activity in rabbits challenged with rLiD1, suggesting
hat this mAb  may  be a promising candidate for therapeutic serum
evelopment or diagnosis in the future.
. Materials and methods
.1.  Animals
Animals were maintained at the Centro de Bioterismo of the
nstituto de Ciências Biológicas of the Federal University of Minas
erais, Brazil and received water and food under controlled envi-
onmental conditions. The investigation conformed to the Guide
or the Care and Use of Laboratory Animals published by the US
ational Institutes of Health (NIH Publication No. 85-23, revised
996) (A5452-01) and was approved by local authorities (proto-
ol #89/11 – Comitê de Ética em Experimentac¸ ão Animal – Federal
niversity of Minas Gerais).
.2. mAbs production
The  rLiD1 from L. intermedia venom [1] was used as immunogen
o BALB/c mice. The animals were immunized four times subcuta-
eously, at approximately 2 weeks intervals, with 10 g of protein
n complete Freund’s adjuvant (Sigma) at the ﬁrst injection, and
ncomplete Freund’s adjuvant (Sigma) at subsequent inoculations.
 booster injection of rLiD1 was made 4 weeks after the fourth
mmunization. Throughout the immunization schedule, mice were
led and the reactivity of immune sera was tested against rLiD1,
. intermedia and L. laeta venoms. Three days after the last injec-
ion, spleen cells from immunized mice were fused with Sp2/0
yeloma cells (ATCC). Supernatants from resulting hybridomas
ere screening by ELISA using L. intermedia and L. laeta venoms.
Abs were puriﬁed on a protein A-sepharose column (GE Health-
are).
.3. Indirect ELISA for the screening of hybridomes
Maxisorp plates (Nunc) were coated overnight at 4 ◦C with a
olution of 1 g/mL of the protein or L. intermedia, L. gaucho or L.
aeta venom in 50 mM Na2CO3, pH 9.0, and blocked with PBS con-
aining 10 g/L BSA. Antibody binding was detected by horseradish
eroxidase conjugated anti-mouse (Sigma) followed by addition
f TMB  solution (Bio-Rad). Washes between steps were done in a
ecan microplate washer. Absorbance values were determined at
50 nm with a Tecan inﬁnite microplate reader.
.4.  Two-dimensional separation of crude venomsHigh-resolution 2D electrophoresis was performed according to
18] with some modiﬁcations. Precast, non-linear immobilized pH
–10 gradient (IPG) strips 7 cm strips (Ready strip, Biorad) were32 (2014) 2086–2092 2087
rehydrated  with 10 g or 20 g of L. intermedia, L. gaucho and L.
laeta venom proteins for 4 h (no electric ﬁeld) and then for 12 h at
30 V. Isoelectric focusing was carried out on the EttanTM IPGphorTM
isoelectric at 20 ◦C using a gradient mode to a total amount of
12 kVh. In the second dimension, proteins and molecular standards
(6.5–200 kDa, Sigma) were separated on 12% SDS-PAGE gel. One
of the gels was stained with silver nitrate and the other was blot-
ted as follows: proteins were electro-transferred to a nitrocellulose
membrane of 0.22 M that was  blocked for 1 h with 3% non-fat
milk in 0.05% Tween 20 in PBS and incubated with the antibody
(hybridoma supernatant in 1:10 dilution) at room temperature
for 1 h. Antibody binding was  detected with a horseradish per-
oxidase (HRPO)-conjugated rabbit anti-mouse secondary antibody
and visualized with a chemiluminescent substrate (Hybond ECL,
Amershan biotech).
2.5.  Peptide synthesis on cellulose membranes and immunoassays
Ninety overlapping pentadecapeptides frameshifted by 3
residues covering the amino acid sequence of LiD1 protein
were prepared by Spot synthesis as previously described [19].
The cellulose membranes were obtained from Intavis (Koln,
Germany); ﬂuorenylmethyloxycarbonyl amino acids and N-
hydroxybenzotriazole were from Novabiochem. A Multipep robot
(Intavis) was used for automated peptide synthesis. After the pep-
tide sequences were assembled, the side-chain protecting groups
were removed by treatment with triﬂuoroacetic acid. The peptide
FDDNANPEYTYHGIP and ﬁfteen of its alanine analogs, the epi-
tope peptide (TYHGIP), peptides changing amino acids next to the
epitope and homolog’s epitope region peptides were prepared as
described above.
After  an overnight saturation step with 3% BSA, the set of mem-
brane bound peptides was probed by incubation with LiD1mAb16
(5 g/mL). Antibody binding was  detected as described in [1].
2.6. Alignment of Loxosceles homolog sequences
Multiple alignment of sequences already classiﬁed in SicTox
groups [14] from L. intermedia, L. gaucho and L. laeta venoms
was carried out using clustal W2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/).  Alignment analysis and editing were done using
Jalview 2.5 [20]. Weblogo was  obtained according to [21].
2.7.  Molecular modeling and epitope localization
The LiD1 model was achieved using LiRecDT1 (PDB accession
code: 3RLH) as the template and employing the molecular mod-
eling package SWISS MODEL [22]. Epitopes were localized in the
three-dimensional model of LiD1 and visualized using PyMol 1.3
(Schrodinger, LLC).
2.8.  In vivo neutralizing assay
Neutralization of dermonecrotic activity of rLiD1 was esti-
mated in rabbits by incubation of 2 MND  of rLiD1 with 0.2 mL  of
LiD1mAb16 (2.5 mg/mL) for 1 h at 37 ◦C (the MND-minimum necro-
tizing dose of the rLiD1 used throughout this study was  10 g).
After incubation, the mixture was injected intradermally (i.d.) into
rabbit dorsum. The local areas of lesions were inspected 48 h after
injection. As the control, rLiD1 alone (2 MND) and rLiD1 after prein-
cubation with the same amount of non-immune mouse IgG were
injected into rabbits, under the same conditions. The diameters of
hemorrhagic and edematogenic lesions were measured with a scale
meter and tachymeters, respectively.
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Fig. 1. Antigenic reactivity of selected monoclonal antibodies (LiD1mAbs). (A) Reactivity of selected LiD1mAbs against L. intermedia venom, L. laeta venom and BSA (negative
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exchanged by alanine all the amino acids close to the common
reactive region (46TYHGIP51) disclosed by the epitope mapping.
The results (Fig. 4A) show that the neighboring amino acids
Fig. 2. LiD1mAb16 cross reactivity among Loxosceles venoms. L. intermedia (A), L.
gaucho (B) and L. laeta (C) venoms were separated by 2DE electrophoresis (ﬁrst
dimension:  IEF pH range 3–10 NL, second dimension: 12% SDS-PAGE) and directly
visualized  by silver nitrate (A–C – pink) or electroblotted onto a nitrocellulose mem-ontrol) using culture cell supernatant (diluted 1:10) was measured by ELISA. (B) Re
ilutions of culture cell supernatant was accessed by ELISA. Results are expressed a
. Results
.1. mAb  production
A  panel of seventeen anti-rLiD1 secreting hybridomas were
elected by screening using L. intermedia and L. laeta venoms as
ntigens coated to ELISA plates. All of the culture cell supernatants
1:10 dilution) of mAbs were reactive with L. intermedia venom
ntigens. Only one clone namely LiD1mAb16 was  also capable of
ross-reacting with the L. laeta venom. Culture cell supernatants
id not bind to BSA, excluding the possibility of non-speciﬁc
inding (Fig. 1A). Other ELISA experiments demonstrated the cross-
eactivity of LiD1mAb16 supernatant against L. intermedia, L. laeta
nd L. gaucho venoms (Fig. 1B) even using 1:1000 supernatant dilu-
ion.
.2. Molecular characterization of LiD1mAb16
For the molecular characterization we have examined initially
he cross-reactivity of LiD1mAb16 by western blot analysis in 2D
DS-PAGE electrophoresis against L. intermedia, L. gaucho and L.
aeta venoms (Fig. 2). LiD1mAb16 was reactive with 34 protein
pots in L. intermedia venom with molecular masses of 29–36 kDa
orresponding to SMases D homologs (Fig. 2A). In L. gaucho venom
iD1mAb16 reacted with 33 proteins spots in same molecular
eight range (Fig. 2B). Similar results were observed for L. laeta
enom, for which LiD1mAb16 interacted with 27 spots in the same
egion (Fig. 2C).
With  the aim of mapping continuous epitopes on LiD1 rec-
gnized by LiD1mAb16 we used SPOT synthesis technique to
repare a set of 90 overlapping peptides (15 residues, frameshifted
y 3 residues) corresponding to the primary sequence of the
iD1 protein. Fig. 3A and B shows the binding pattern of
iD1mAb16 with the overlapping peptides. Four peptides in
he N-terminal part (spots 13–16) were strongly recognized.
ig. 3B shows the amino acid sequence of reactive peptides. They
orrespond to 37FDDNANPEYTYHGIP51, 40NANPEYTYHGIPCDC54,
3PEYTYHGIPCDCGRN57 and 46TYHGIPCDCGRNCKK60. The reactive
eptides exhibit a common 6-residue motif 46TYHGIP51. To visu-
lize the position of experimentally determined epitopes, LiD1
rotein structure was modeled by homology using the X-ray struc-
ure of LiRecDT1 from L. intermedia [23]. The localization of the
6TYHGIP51 epitope in the context of the three-dimensional struc-
ure of the dermonecrotic protein is shown in Fig. 3 C. The epitopic
egion found is located in the catalytic loop region [23].ty of LiD1mAb16 against L. intermedia, L. gaucho and L. laeta venoms using different
n ± SEM of the absorbance value of triplicates.
To characterize the critical amino acid residues in the LiD1
epitope recognized by LiD1mAb16, a series of alanine analogs of
peptide 13 (37FDDNANPEYTYHGIP51) was  prepared by SPOT syn-
thesis. The results (Fig. 3D) revealed that some residues in the
peptide sequence could not be modiﬁed by alanine without a
decrease of at least 70% in the reactivity with the antibody: this
is the case of Thr46, His48 and Gly49. Some other residues located
close to the crucial residues, such as Asn42, Pro43, Tyr47, Ile50, seem
also to be important for antibody binding.
In order to investigate the role of neighboring amino acids webrane for immunoblot analysis (green). Membranes were blotted with 20 g of the
venom and were incubated with LiD1mAb16. Merged areas are shown in black,
images  alignment was  made using Progenesis Samespot® software. (For interpreta-
tion  of the references to color in this ﬁgure legend, the reader is referred to the web
version of the article.)
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Fig. 3. LiD1mAb16 key epitope residues. (A) Reactivity of 15-mer overlapping peptides derived from the amino acid sequence of LiD1 (top left). Peptides were prepared
by the Spot method on cellulose membranes and LiD1mAb16 binding (5 g/mL) to cellulose-bound peptides was detected by a peroxidase-coupled anti-mouse antibody
(diluted 1:2000). (B) The reactive peptides are numbered 13–16. The amino acid sequence shared in all peptides sequences is shown in red and it is localized in LiD1 3D
structure (C). His48 from active site involved in the epitope is highlighted (red). (D) A series of alanine analogs of peptide 13 were prepared by Spot synthesis and further
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Erobed by LiD1mAb16. The reference peptide is at position 1 and each further spo
iD1mAb16 with the reference peptide (ﬁrst bar) or with an analog peptide in which
o  color in this ﬁgure legend, the reader is referred to the web version of the articleannot be replaced by alanine without a loss of 60% or greater
f reactivity with the antibody. The common region was also syn-
hesized as such and surprisingly showed a better reactivity than
he other peptides (70% of reactivity compared with the control
ig. 4. Importance of neighboring amino acids in LiD1mAb16 epitope and minimum epi
ynthesis and further probed by LiD1mAb16. The reference peptide 13 is at position 1. Eac
reserved sequence. The last peptide corresponds to epitope sequence alone. (B) Two p
hich did not seem to be as key for binding were prepared by Spot synthesis and furthe
ach  further spot corresponds to an analog excluding at least one C-terminal residue. Pepesponds to an alanine analog. Each bar represents the intensity of the binding of
ndicated residue has been replaced by alanine. (For interpretation of the referencespeptide).  As the peptide containing only the six common amino
acids was  reactive, our next step was to examine the minimum
epitope of LiD1mAb16. From the six residues of the epitope region
(46TYHGIP51), three were seen to be key in antibody recognition
tope. (A) Analogs of the peptide 13 of LiD1 spot membrane were prepared by Spot
h further spot corresponds to an alanine analog with only the epitope region having
eptides containing only the epitope sequence and excluding amino acid residues,
r probed by LiD1mAb16. The reference epitope peptide (TYHGIP) is at position 1.
tides were prepared by the Spot method and tested as described in the text.
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Fig. 5. LiD1mAb16 epitope in Loxosceles SMases D homologs. (A) Alignment of available L. intermedia, L. Laeta e L. gaucho SMases D homolog sequences. Key epitope residues
are  colored in orange. Secondary structure of SMase I (AAM21154; PDB accession code 1XX1), consensus logo and consensus sequence are shown underneath the alignment.
In  the right top of the panel, SicTox group of each sequence [14] and LiD1mAb16 epitope consensus logo of each SicTox group. (B) Two peptide sequences shifting key amino
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iD1mAb16. The reference peptide is at position 1. Each further spot corresponds to 
egend,  the reader is referred to the web version of the article.)
y alanine scanning (Thr46, His48 and Gly49). In addition, with this
xperiment we observed a loss of antibody binding in 40 and 75%,
fter deletion of the C-terminal residues: Ile50 and Pro51 (Fig. 4B).
Fig. 5 shows the multiple sequence alignment of 33 mature
equences of SMase D homologs from the venom of L. intermedia, L.
aucho and L. laeta. The three key residues of the epitope identiﬁed
y alanine scanning (shown in orange) are residues strictly (His48
nd Gly49) or functionally (Thr46) conserved in all sequences ana-
yzed. The His48 is conserved among sequences, since it is involved
n the catalytic activity of SMases D. The sequences were organized
ccording to their SicTox group and each group was  submitted to
 WebLogo at the epitope region (Fig. 5, top right), group SicTox
II and ID were not submitted, since there is only one sequence
or each. WebLogo of the groups conﬁrms that residue Thr46 can be
eplaced by serine in some sequences of the group SicTox III and
y methionine in the group SicTox IA (the same was observed in
equence ABD91847, which belongs to the group ID). Next, with
he aim of determining whether shifting in position 46 would affect
ntibody recognition, the epitope region was synthesized replac-
ng threonine by serine or methionine (Fig. 5, right bottom). The
iD1mAb16 was able to recognize all the peptides; however the
eptide with a serine in the place of the threonine had a loss of 50%
n the reactivity.6) in SMases D homologs were prepared by Spot synthesis and further probed by
es with shifting residues. (For interpretation of the references to color in this ﬁgure
3.3. In vivo neutralization assay
The percentage of inhibition of dermonecrotic, hemorrhagic
and oedematogenic activities caused by rLiD1 was  assessed by
pre-incubation of LiD1mAb16 for 1 h at 37 ◦C with two  minimum
necrotizing doses (2 MND) of rLiD1 corresponding to 20 g of pro-
tein in a total volume of 200 L and then injected intradermal into
naïve rabbits (Fig. 6C). As control, the protein was injected alone
(Fig. 6A) or after incubation with non-immune mouse IgG under
same conditions (Fig. 6B). An inhibition of 80% of the dermonecrotic
activity and of 82% of hemorrhagic activity by LiD1mAb16 was
observed, while non-immune mouse IgG was  not at all protec-
tive. Concerning the oedematogenic activity induced by rLiD1, it
was inhibited to 48% after the pre-incubation with the mAb  while
non-immune mouse IgG was not capable of reducing this activity.
4.  Discussion
We  have described the development of a neutralizing mAb  with
a broad cross-reactivity toward many antigens from three differ-
ent venoms, which protects rabbits against dermonecrotic toxin
activity. Other mAbs against L. laeta and L. intermedia spiders whole
venoms have already been produced, however these mAbs failed
C. Dias-Lopes et al. / Vaccine 32 (2014) 2086–2092 2091
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aig. 6. Neutralization capacity of LiD1mAb16 against rLiD1. Rabbits were injected i.d
ouse IgG (B) or LiD1mAb16. The dermonecrotic lesions were observed 48 h after i
o recognize and neutralize the toxic components of venoms from
eterologous species [24,25].
Due to the similarity between sphingomyelinase D toxins, the
ajor toxic components from the Loxosceles spider venoms, we
sed a recombinant dermonecrotic protein from L. intermedia [1,26]
s immunogen to obtain mice hybridomas. Previous works support
he feasibility of using recombinant SMases for the production of
eutralizing polyclonal and polyvalent anti-Loxosceles antivenoms
27–29]. Seventeen anti-rLiD1 hybridomas were obtained from the
nitial screening, all displaying afﬁnity for L. intermedia venom anti-
ens. However, of 17 anti-rLiD1 reactive with L. intermedia mAbs,
nly one displayed cross-reactivity with proteins of L. laeta and L.
aucho venom antigens. This result conﬁrms the previous obser-
ation that mAbs produced against Loxosceles venoms are mostly
pecies-speciﬁc, differing from cross-reactive polyclonal antibodies
25,30].
The polyvalent mAb  named LiD1mAb16 recognizes at least 25
roteins in each Loxosceles venom tested. The diversity of spots
evealed by the antibodies could be explained by the site of recog-
ition of the mAb  (catalytic site, which is very conserved among
Mase D homologs, as showed by Fig. 5) and also by the high num-
er of homologs described until now (more than 168 sequences
s reported by [14]). We  believe that all spots recognized by the
ntibody are phospholipases D molecules since they are in the
olecular range of these proteins. The other two  main compo-
ents of L. intermedia venom besides phospholipases D have lower
olecular mass (insecticidal peptides) than the spots recognized by
iD1mAb16 or lower molecular mass and higher isoelectric points
astacin-like metalloproteases) [31,32]. Besides, since only one (out
f seventeen) clones was cross-reactive between Loxosceles ven-
ms, it would be hard to imagine that the only cross-reactive mAb
ound until know could recognize more than one class of enzymes
rom the venom. L. gaucho proteome analysis showed that venom
rom the same species could contain a large number of proteins (at
east 8) [33]. The transcriptome of L. intermedia showed a total 160
STs encoding phospholipases D like toxins with 23 clusters formed
y these ESTs, these data provide some evidence of the presence of
 high number of homologs in the same venom [31].
We  mapped the epitope recognized by LiD1mAb16
ia  its binding to a set of overlapping peptides covering
he amino acid sequence of LiD1. The mapping of epi-
opes recognized by LiD1mAb16 indicated that the region
7FDDNANPEYTYHGIPCDCGRNCKK60, encompassed in the cat-
lytic loop of SMases D and which includes histidine 48, an amino
cid involved in the catalytic activity of these enzymes [23], is the
ain epitope recognized. All the peptides bound by LiD1mAb16
hared the sequence 46TYHGIP51 that contains amino acids that
ere shown by alanine scanning experiments to be important for
iD1mAb16 binding, the catalytic charged residue (His48), a polar
esidue (Thr46) and a non-charged residue (Gly49). Two of three
iD1mAb16 key epitope residues (histidine 48 and glycine 49)
re strictly conserved among the sequences of SMase D homologs2 MND of rLiD1 which was  preincubated for 1 h, at 37 ◦C with PBS (A) or non-immune
on.
of  L. intermedia, L. gaucho and L. laeta venoms, explaining the
cross-reactivity of these antibody. The other residue (Thr46) is
conserved in 67% of the sequences analyzed. In SicTox III group
it is replaced by serine and in SicTox IA and ID groups it is
replaced by methionine.
The  hexapeptide 46TYHGIP51 alone was  recognized by
LiD1mAb16, although with a lower efﬁcacy than the reference
peptide. When this epitope was  surrounded by alanine residues,
antibody reactivity with LiDmAb16 was lost, probably because the
number of possible conformations of the peptide was  increased
or some residues important for binding were not replaceable by
alanine. The original residues might play a role in the structure of
the peptide, reducing the number of degrees of freedom and/or
stabilizing the interaction with the antibody. We  also checked
out if 46TYHGIP51 was  the minimum epitope. Once this region
comprises residues 46–51 and the key residues are 46, 48 and 49,
we tried to eliminate residues 50 and 51. The removal of residues
50 and 51 provoked a loss of 75% of the reactivity compared to
reference peptide, meaning that the six-residue sequence cannot
be C-terminally further shortened.
The interaction of LiD1mAb16 with an epitope inside the cat-
alytic loop of LiD1, including the catalytic hystidine 48 and the
surrounding glycine 49 and threonine 46, provides a plausible
explanation for the neutralizing capacity of this antibody. About
80% of protection against necrotic and hemorrhagic activities was
obtained by pre-incubation of the mAb  with rLiD1. Concerning the
protection against oedematogenic activity, the level of neutraliza-
tion was smaller (48%), although signiﬁcant. All these results are
very similar with those obtained with polyclonal antibodies against
synthetic epitopes [18,34,35] with, however, the advantage associ-
ated with monoclonal antibodies, i.e., a controlled and reproducible
production.
In conclusion, our results show the generation and character-
ization of a neutralizing mAb produced against a dermonecrotic
protein of L. intermedia venom able to recognize more than 25 pro-
teins (at SMases D molecular mass range) in each of the medically
important Loxosceles whole venoms. These results conﬁrm the per-
spective of utilization of mAbs for therapeutic approaches and also
in diagnosis assays against loxoscelism.
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